Open access
Open access
Powered by Google Translator Translator

Oncology (all articles)

RCT: Lenvatinib plus pembrolizumab improve outcomes compared to chemotherapy in patients with advanced endometrial cancer.

21 Jan, 2022 | 09:46h | UTC

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine

 

Commentary on Twitter

 


Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.

21 Jan, 2022 | 09:36h | UTC

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline – Journal of Clinical Oncology

Related: EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumors.

 


15th Report on Carcinogens now includes 256 listings of substances that are known or reasonably anticipated to cause cancer in humans.

21 Jan, 2022 | 09:34h | UTC

15th Report on Carcinogens – National Toxicology Program

 

Commentary on Twitter

 


The validity of progression-free survival 2 as a surrogate trial end point for overall survival.

21 Jan, 2022 | 09:31h | UTC

The validity of progression-free survival 2 as a surrogate trial end point for overall survival – Cancer (link to abstract – $ for full-text)

 


RCT: In patients with previously untreated Diffuse Large B-Cell Lymphoma, a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab, was associated with improved outcomes compared to standard R-CHOP treatment.

21 Jan, 2022 | 09:28h | UTC

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

 


O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee.

20 Jan, 2022 | 08:59h | UTC

O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee – Radiology

 


Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.

20 Jan, 2022 | 08:57h | UTC

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update – Journal of Clinical Oncology

 

Commentary on Twitter

 


RCT: Prolonging prophylactic intravenous antibiotic regimens not beneficial after endoprosthetic reconstruction for lower extremity bone tumors.

19 Jan, 2022 | 08:37h | UTC

Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial – JAMA Oncology

Commentary: No Benefit Seen With Longer Antibiotic Course After Surgery for Bone Tumors – Cancer Therapy Advisor

 


ASTRO issues clinical guideline on external-beam radiation therapy for primary liver cancers.

19 Jan, 2022 | 08:36h | UTC

ASTRO Issues Clinical Guideline on External-Beam Radiation Therapy for Primary Liver Cancers – The ASCO Post

Original Article: External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline – Practical Radiation Oncology

 


M-A: Beta-blockers and renin–angiotensin system inhibitors may provide a modest benefit for the preservation of left ventricular function in patients with breast cancer treated with anthracyclines or trastuzumab.

19 Jan, 2022 | 08:34h | UTC

A systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer – European Journal of Cardiology (link to abstract – $ for full-text)

Commentary: BBs, ACEI/ARBs to Prevent LV Dysfunction Due to Breast Cancer Drugs – American College of Cardiology

 


A single-arm study evaluated Naive T-Cell depleted peripheral blood stem-cell grafts for the prevention of chronic graft-versus-host disease.

19 Jan, 2022 | 08:22h | UTC

Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease – Journal of Clinical Oncology

Commentary: New graft strategy may improve outcomes for blood stem cell recipients – University of Pittsburg

 


M-A: Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and esophagectomy.

19 Jan, 2022 | 08:19h | UTC

Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Prolonged follow-up of RCT: Emission Tomography–driven strategy in advanced Hodgkin Lymphoma.

19 Jan, 2022 | 08:16h | UTC

Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


Dermatologic immune-related adverse events: the toxicity spectrum and recommendations for management.

19 Jan, 2022 | 08:15h | UTC

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management – International Journal of Women’s Dermatology

Related: Management of Dermatologic Adverse Events from Cancer Therapies

 


Study shows many patients with metastatic cancer near the end of life still receive guideline-nonconcordant radiotherapy.

18 Jan, 2022 | 09:35h | UTC

Assessment of Guideline-Nonconcordant Radiotherapy in Medicare Beneficiaries With Metastatic Cancer Near the End of Life, 2015-2017 – JAMA Health Forum

Commentary: Study: Cancer patients given high-dose radiation treatments even near end of life – UPI

 


Review: Imaging of prostate cancer.

18 Jan, 2022 | 09:20h | UTC

Imaging of Prostate Cancer – Deutsches Ärzteblatt International

Related:

ASCO Guideline: Optimum Imaging Strategies for Advanced Prostate Cancer

RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.

RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer

Meta-Analysis: Negative Predictive Value of MRI in the Detection of Clinically Significant Prostate Cancer

Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis

Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management

Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer

Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer

RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.

Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy

Research: Biparametric MRI (simpler, faster) May Be Used to Exclude Aggressive Disease and Avoid Unnecessary Biopsies in Men with Clinical Suspicion of Prostate Cancer

Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer

 


ASCO Guideline: Management of stage III non–small-cell lung cancer.

18 Jan, 2022 | 09:12h | UTC

Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline – Journal of Clinical Oncology

 


Adjuvant Capecitabine for early breast cancer: 15-year overall survival results from a randomized trial.

18 Jan, 2022 | 09:11h | UTC

Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial – Journal of Clinical Oncology

 


RCT: Paclitaxel and Carboplatin noninferior to Paclitaxel and Ifosfamide in patients with carcinosarcoma of the uterus or ovary.

18 Jan, 2022 | 09:10h | UTC

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Paclitaxel Plus Carboplatin Is Reportedly Non-Interior to Paclitaxel and Ifosfamide in Uterine Carcinosarcoma – Cancer Network

 


RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.

18 Jan, 2022 | 09:08h | UTC

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)

 


Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.

16 Jan, 2022 | 22:41h | UTC

Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge – Nature Medicine

Commentary: Large international evaluation shows AI accurately diagnoses prostate cancer – Karolinska Institutet

 

Commentary from one of the authors on Twitter (thread – click for more)

 


U.S. Cancer statistics, 2022.

16 Jan, 2022 | 22:39h | UTC

Cancer statistics, 2022 – CA: A Cancer Journal for Clinicians

 


RCT: Nivolumab plus chemotherapy improved progression-free survival, but not overall survival, compared to placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer.

16 Jan, 2022 | 22:38h | UTC

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 


Hallmarks of Cancer: New Dimensions.

14 Jan, 2022 | 08:12h | UTC

Hallmarks of Cancer: New Dimensions – Cancer Discovery

 

Commentary on Twitter

 


Preliminary findings from a randomized trial showed promising results from dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

14 Jan, 2022 | 08:03h | UTC

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer – Nature

Commentary: KEYNOTE-811: Pembrolizumab combination as a potentially transformative treatment for HER2-positive gastric cancer – Vall d’Hebron University Hospital

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.